Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a low-dose epilepsy drug protect aging brains from dementia?

NCT ID NCT06919926

First seen Apr 17, 2026 · Last updated May 01, 2026 · Updated 3 times

Summary

This study tests whether a low-dose, slow-release form of levetiracetam (AGB101) can reduce overactivity in a key memory region of the brain in healthy older adults. Overactivity in this area is linked to higher dementia risk. Sixty participants aged 50-80 will receive both the drug and a placebo in random order, each for two weeks, and brain scans will measure changes. The goal is to see if the drug safely calms this brain activity, potentially paving the way for future dementia prevention.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEMENTIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Johns Hopkins University School of Medicine

    RECRUITING

    Baltimore, Maryland, 21287, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.